pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 17·1 min read
save

Ichnos Glenmark Innovation appoints Mariana Cota Stirner as chief medical officer

Jul 17, 2026·read at STAT ↗Neutral

Ichnos Glenmark Innovation announced the appointment of a new chief medical officer.

Mariana Cota Stirner will assume the role, bringing experience from her recent position as fractional chief medical officer and head of clinical development at Azalea Therapeutics.

Prior to that, she served as vice president and therapeutic area head of hematology at AbbVie, overseeing the company's hematology portfolio.

The hire underscores Ichnos Glenmark Innovation's effort to strengthen its clinical leadership as it advances its pipeline.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Up and down the ladder: The latest comings and goings”

read at STAT ↗
481 words · retrieved Jul 17
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ichnos Glenmark Innovation3ABBVIE2RISING2
topics
Hematology3

related stories

  • 14h agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • Jul 31Syphilis spreads while researchers contend with federal constraints and a drug shortageSTAT
  • Jul 30Ebola outbreak nears milestone, while a vaccine remains months awaySTAT
  • Jul 28Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen optionsFierce Biotech
  • Jul 27FDA approves Freenome colorectal cancer blood test to be marketed by AbbottFierce Biotech